Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

PHASE3CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Intraocular MelanomaMelanoma (Skin)Metastatic Cancer
Interventions
DRUG

melphalan

Given throug isolated hepatic artery infusion

DRUG

regional chemotherapy

Patients receive the best alternative therapy

DRUG

systemic chemotherapy

Patients receive the best alternative therapy

PROCEDURE

hepatic artery embolization

Patients receive the best alternative therapy

Trial Locations (12)

12208

Cancer Center of Albany Medical Center, Albany

15232

UPMC Cancer Centers, Pittsburgh

18015

St. Luke's Cancer Network at St. Luke's Hospital, Bethlehem

21201

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore

80113

Swedish Medical Center, Englewood

90404

John Wayne Cancer Institute at Saint John's Health Center, Santa Monica

33612-9497

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda

07962-1956

Carol G. Simon Cancer Center at Morristown Memorial Hospital, Morristown

43210-1240

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus

97213-2967

Providence Cancer Center at Providence Portland Medical Center, Portland

77555-0361

University of Texas Medical Branch, Galveston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Delcath Systems Inc.

INDUSTRY

NCT00324727 - Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma | Biotech Hunter | Biotech Hunter